Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amgen, Inc. (AMGN) vs JPMorgan Ultra Short Income ETF (JPST) Price & Performance

Amgen, Inc.Trade
JPMorgan Ultra Short Income ETFTrade

Price performance (Past 24H)

Key statistics

Amgen, Inc. vs JPMorgan Ultra Short Income ETF — how do they compare? Amgen, Inc. trades at $412.21 (market cap $224.14B), while JPMorgan Ultra Short Income ETF trades at $50.45. The key difference: Amgen, Inc. pays a 2.43% dividend while JPMorgan Ultra Short Income ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, JPMorgan Ultra Short Income ETF nearer its low. Which is the better fit depends on your goals.

AMGNJPST
Market Cap
$224.14B
Sector
HealthLeveraged / Inverse
52-Week High
$417.20$50.78
52-Week Low
$271.18$50.40
Enterprise Value
$267.45B
Dividend Yield
2.43%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

Read more on AMGN

About JPMorgan Ultra Short Income ETF

JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.

Read more on JPST